HOUSE_OVERSIGHT_024820.jpg
1.64 MB
Extraction Summary
3
People
13
Organizations
0
Locations
0
Events
1
Relationships
3
Quotes
Document Information
Type:
Financial research report / market analysis
File Size:
1.64 MB
Summary
This document is page 4 of a Cowen 'Collaborative Insights' market research report dated February 25, 2019. It analyzes the market for cannabinoids (CBD), focusing on synthetic biology production methods, laboratory testing opportunities for life science companies, and the perspectives of drug retailers and insurance payors regarding coverage and sales. The document bears a 'HOUSE_OVERSIGHT_024820' Bates stamp, indicating it was part of a production to the House Oversight Committee, likely related to financial investigations.
People (3)
| Name | Role | Context |
|---|---|---|
| Schenkel | Analyst/Author |
Author of the section regarding Synthetic Biology and Life Science Tools.
|
| Rhyee | Analyst/Author |
Author of the section regarding Retailer and Payor Perspectives.
|
| Michael Cella | Recipient |
Named in the watermark as the intended recipient of the report (michael.cella@cowen.com).
|
Organizations (13)
Relationships (1)
Watermark states 'This report is intended for michael.cella@cowen.com'
Key Quotes (3)
"Synthetic biology methods, which harness fermentation to produce cannabinoids, are particularly attractive considering they can potentially produce a variety of cannabinoids while being highly scalable, efficient, and environmentally friendly."Source
HOUSE_OVERSIGHT_024820.jpg
Quote #1
"Large pharmacy chains, such as CVS and Walgreens, don't currently sell CBD oil, but WBA noted it is monitoring the CBD market."Source
HOUSE_OVERSIGHT_024820.jpg
Quote #2
"Currently, CBD products are not a covered benefit, or an extra benefit, that has been approved by CMS or states"Source
HOUSE_OVERSIGHT_024820.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document